Search Results - "O'Reilly, E.M."

LBA53 Alliance A021602: Phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET) by Chan, J., Geyer, S., Ou, F-S., Knopp, M., Behr, S., Zemla, T., Acoba, J., Shergill, A., Wolin, E.M., Halfdanarson, T.R., Trikalinos, N., Konda, B., Vijayvergia, N., Dasari, N.A., Strosberg, J., Kohn, E.C., Kulke, M.H., O'Reilly, E.M., Meyerhardt, J.A.

Get full text

Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b–based chemoradiation: ACOSOG Trial Z05031 by Picozzi, V.J., Abrams, R.A., Decker, P.A., Traverso, W., O'Reilly, E.M., Greeno, E., Martin, R.C., Wilfong, L.S., Rothenberg, M.L., Posner, M.C., Pisters, P.W.T.

“…The American College of Surgeons Oncology Group sought to confirm the efficacy of a novel interferon-based chemoradiation regimen in a multicenter phase II…”
Get full text

A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression by Li, D, Pant, S, Ryan, D.P, Laheru, D, Bahary, N, Dragovich, T, Hosein, P.J, Rolfe, L, Saif, M.W, LaValle, J, Yu, K.H, Lowery, M.A, Allen, A, O'Reilly, E.M

“…Abstract Background Nucleotide transporters such as human equilibrative nucleoside transporter-1 (hENT1) play a major role in transporting gemcitabine into…”
Get full text

Pancreatic adenocarcinoma in a young patient population-12-year experience at Memorial Sloan Kettering Cancer Center by Duffy, A., Capanu, M., Allen, P., Kurtz, R., Olson, S.H., Ludwig, E., Klimstra, D.S., O'Reilly, E.M.

“…Background There is a dearth of data in a younger population of patients with pancreatic ductal adenocarcinoma (PAC) regarding epidemiology, genetics,…”
Get full text

Prognostic Value of CA19-9 Level for Locally Advanced Pancreatic Cancer by Abreu, A, Ho, A.Y, Huguet, F, Kuk, D, Zhang, Z, O'Reilly, E.M, Goodman, K.A

Get full text

6591 POSTER Improved 6-month Survival Rate in Subjects With Prostate Stem Cell Antigen (PSCA) Positive Tumours in a Global, Randomized Phase 2 Trial Comparing Gemcitabine Vs. Gemcitabine + Ags-1c4d4 (asp6182) in Metastatic Pancreatic Cancer (mPC) by Wolpin, B.M, O'Reilly, E.M, Ko, Y.J, Lima, M.S. Rocha, Spratlin, J.L, Macarulla, T, Pezet, D, Hartford, A, Jackson, L.S, Hidalgo, M

Get full text

Combining tumor deposits with the number of lymph node metastases to improve the prognostic accuracy in stage III colon cancer: a post hoc analysis of the CALGB/SWOG 80702 phase III study (Alliance) by Cohen, R., Shi, Q., Meyers, J., Jin, Z., Svrcek, M., Fuchs, C., Couture, F., Kuebler, P., Ciombor, K.K., Bendell, J., De Jesus-Acosta, A., Kumar, P., Lewis, D., Tan, B., Bertagnolli, M.M., Philip, P., Blanke, C., O'Reilly, E.M., Shields, A., Meyerhardt, J.A.

“…In colon cancer, tumor deposits (TD) are considered in assigning prognosis and staging only in the absence of lymph node metastasis (i.e. stage III pN1c…”
Get full text

Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity? by Sahin, I.H., Askan, G., Hu, Z.I., O’Reilly, E.M.

“…The genomic-plasticity of the immune system creates a broad immune repertoire engaged to tackle cancer cells. Promising clinical activity has been observed…”
Get full text

Intensity-modulated Radiotherapy and Concurrent Chemotherapy for Locally Advanced and Resected Pancreatic Cancer: Evaluation of Toxicity and Disease Control Outcomes by Wu, A.J, Jacks, L.M, Zhang, Z, Ho, A.Y, O'Reilly, E.M, Kowalski, A.V, Kim, B.H, Goodman, K.A

Get full text

597P Surgical quality for patients (pts) treated with neoadjuvant chemotherapy vs chemoradiation for locally advanced rectal cancer (LARC): PROSPECT (NCCTG N1048, alliance) by Weiser, M., Shi, Q., Chang, G.J., Hakki, L., Goldberg, J., Auer, R., Gollub, M., Saltz, L., Musher, B.L., Al baghdadi, T., Farma, J., George, T., Colgrove, B., Nelson, G., O'Reilly, E.M., Shergill, A., Meyerhardt, J., Mamon, H., Schrag, D.

Get full text

1626P A novel endoscopic ultrasound guided extended-release siRNA implant targeting KRASG12D/V in localized pancreatic cancer by Varghese, A.M., Golan, T., Schattner, M., Ang, C., Gutierrez, M., Passhak, M., Geva, R., Yarom, N., Ligresti, R., Khamaysi, I., Bhutani, M.S., Matalon, S., Pollack-Shragai, O., Rom, D.M., Shirvan, M., Javle, M., O'Reilly, E.M.

Get full text

Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer by Bendell, J., O'Reilly, E.M., Middleton, M.R., Chau, I., Hochster, H., Fielding, A., Burke, W., Burris, H.

“…We identified olaparib 100 mg b.i.d. (intermittent) with gemcitabine 600 mg/m2 as a tolerated dose combination, which could be considered for future…”
Get full text

Survival after surgery for LAPC depends on post-induction CA19-9, CA19-9 decrease, and performance status by Dekker, E.N., van Klaveren, D., Janssen, Q.P., Besselink, M.G., Katz, M.G., O'Reilly, E.M., Tzeng, C.-W.D., Wei, A.C., Zureikat, A.H., Koerkamp, B. Groot

Get full text

1619P Health-related quality of life with nalirifox versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): EORTC QLQ-C30 results from the NAPOLI 3 trial by Melisi, D., Macarulla, T., de la Fouchardiere, C., Pazo Cid, R.A., Chandana, S., Dean, A., Kiss, I., Lee, W., Goetze, T.O., Van Cutsem, E., Paulson, A.S., Bekaii-Saab, T., Pant, S., Hubner, R., Xiao, Z., Zhang, L., Benzaghou, F.M., O'Reilly, E.M., Wainberg, Z.A.

Get full text

1618P Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC) by Schram, A., Macarulla, T., Cleary, J., Neuzillet, C., Arnold, D., Reiss, K.A., Bekaii-Saab, T., Rodon, J., Goto, K., Rha, S.Y., Duruisseaux, M., Leighl, N., Weinberg, B.A., Al-Hallak, M.N., Joe, A.K., Adeyemi, S., Wasserman, E., Koeman, K-J., Drilon, A., O'Reilly, E.M.

Get full text

Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC) by Duffy, A., Capanu, M., Abou-Alfa, G.K., Huitzil, D., Jarnagin, W., Fong, Y., D'Angelica, M., DeMatteo, R.P., Blumgart, L.H., O'Reilly, E.M.

“…Background The incidence of gallbladder cancer (GBC) in the US is 1.2/100,000. This report examines the patterns of presentation, adjuvant treatment and…”
Get full text

Distinct genomic profiles are associated with minimal pathological response to preoperative hepatic artery infusion chemotherapy in initially unresectable colorectal liver metastases by Nasar, N., Datta, J., Evenhaim, M.T, Chou, J., Gonen, M., Soares, K., Balachandran, V., Drebin, J., Kingham, T.P., Wei, A.C., Jarnagin, W.R., Cercek, A., O'Reilly, E.M., Connell, L., Kemeny, N., D'Angelica, M.I.

Get full text

1527P Assessing clinical benefit of olaparib maintenance treatment in subgroups of patients with germline BRCA mutation (gBRCAm) and metastatic pancreatic cancer: Phase III POLO trial by Hochhauser, D., Kindler, H., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M.J., Park, J.O., Arnold, D., Oh, D-Y., Reinacher-Schick, A., Tortora, G., Algül, H., O'Reilly, E.M., McGuinness, D., Cui, K., Schlienger, K., Locker, G., Golan, T.

Get full text

1468P POLO: Subsequent therapy after maintenance olaparib in patients with a germline BRCA mutation and metastatic pancreatic cancer by Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla Mercade, T., Hall, M.J., Park, J.O., Hochhauser, D., Arnold, D., Oh, D-Y., Reinacher-Schick, A., Tortora, G., Algül, H., O'Reilly, E.M., Bordia, S., McGuinness, D., Cui, K.Y., Locker, G., Kindler, H.

Get full text

1467P POLO: Long-term safety and tolerability of olaparib for patients with a germline BRCA mutation and metastatic pancreatic cancer by Arnold, D., Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla Mercade, T., Hall, M.J., Park, J.O., Hochhauser, D., Oh, D-Y., Reinacher-Schick, A., Tortora, G., Algül, H., O'Reilly, E.M., Bordia, S., McGuinness, D., Cui, K.Y., Locker, G., Kindler, H.

Get full text